NovoCure Limited - Ordinary Shares (NVCR) Company Bio
NovoCure Limited is a commercial stage oncology company which develops treatment for solid tumor cancers therapy called the tumor treating fields. The company was founded in 2000 and is based in Saint Helier, Channel Islands.
NVCR Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for NovoCure Ltd. To summarize, we found that NovoCure Ltd ranked in the 85th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 941.5%. In terms of the factors that were most noteworthy in this DCF analysis for NVCR, they are:
The business' balance sheet suggests that 1% of the company's capital is sourced from debt; this is greater than merely 6.15% of the free cash flow producing stocks we're observing.
As a business, NovoCure Ltd experienced a tax rate of about 211% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than 98.16% of stocks generating free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as NVCR, try ARGX, HCA, NHC, FVE, and VMD.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) (the first subject has been dosed in a Phase 3 trial evaluating etrasimod for the potential treatment of moderately to severely active ulcerative colitis) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) (announced a deal with Russia for 100 million doses of Sputnik-V vaccine against the coronavirus) Fortress Biotech (NASDAQ: FBIO ) Guardant Health Inc (NASDAQ: GH ) Immunovant Inc (NASDAQ: IMVT ) Insmed Incorporated (NASDAQ: INSM ) InVitae Corp (NYSE: NVTA ) ...
Even as COVID-19 is wreaking havoc across the world, cancer continues to kill about 10 million people per year, and the quest for the most effective cure is gaining pace. In fact, the coronavirus pandemic has reportedly accelerated the cancer fatality rate, further stressing the urgent need to scale up oncology research. Thanks to the […]